Atlas Trials

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Clinical trial NCT06592924 · RECRUITING

Trial details

NCT number
NCT06592924
Sponsor
Canadian Cancer Trials Group
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Prostate Cancer (Adenocarcinoma)
Start date
2025-05-28
Primary completion
2031-03-14
Enrollment
830

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.